IP Library › Granted Patent US 8,329,172
Granted Patent B2
US 8,329,172 · App. 11/840,956 · Granted Dec 11, 2012

Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,172
App. No.
11/840,956
Granted
Dec 11, 2012
Kind
B2
Abstract

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.

Claims (1)

1. A method of treating low grade B-cell non-Hodgkin's lymphoma in a human patient comprising administering to the patient chemotherapy consisting of CVP therapy to which the patient responds, followed by rituximab maintenance therapy, wherein the maintenance therapy comprises four weekly administrations of rituximab at a dose of 375 mg/m 2 every 6 months, and wherein the maintenance therapy is provided for 2 years.

Assignments (2)
CHANGE OF NAME Recorded Apr 30, 2015
From: BIOGEN IDEC INC.
To: BIOGEN INC.
Reel/Frame 035552/0202 →
CHANGE OF NAME Recorded Jun 1, 2011
From: IDEC PHARMACEUTICALS CORPORATION
To: BIOGEN IDEC INC.
Reel/Frame 026371/0651 →